Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.
In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.
Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.
With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.
Johnson & Johnson (NYSE: JNJ) reported positive preliminary results from the South African Phase 3b Sisonke study, indicating an 85% effectiveness of its COVID-19 vaccine booster against hospitalization during the Omicron variant surge. The study involved healthcare workers and revealed that vaccine effectiveness increased over time post-boost. Additionally, a separate analysis showed that a heterologous booster regimen significantly enhanced immune responses compared to a homologous booster. These findings underscore the robustness of the Johnson & Johnson vaccine amidst evolving COVID-19 variants.
The CHMP of the EMA issued a Positive Opinion for Johnson & Johnson's COVID-19 vaccine booster, recommending it for adults 18+ at least two months post-initial vaccination. The booster increased protection to 75% against symptomatic COVID-19 and demonstrated 100% protection against severe cases, with data from the Phase 3 ENSEMBLE 2 study. The vaccine was generally well-tolerated, showing no new safety concerns. The recommendation supports its use as a 'mix and match' booster.
Johnson & Johnson (NYSE: JNJ) will hold a conference call on January 25, 2022, at 8:30 a.m. Eastern Time to discuss its fourth-quarter results. The call will feature key executives, including Joaquin Duato, the incoming CEO. Investors can access the call via the company's website and by phone. A replay will be available until February 8, 2022. The earnings report will be released at approximately 6:45 a.m. Eastern Time on the same day. For future events, please visit Johnson & Johnson's investor relations page.
Johnson & Johnson (NYSE: JNJ) received interim recommendations from the WHO's Strategic Advisory Group of Experts (SAGE) supporting its COVID-19 vaccine as a booster shot for individuals 18 and older, to be given 2 to 6 months post the primary vaccination. The booster enhances protection against symptomatic infections and severe disease. The recommendations are based on data from clinical trials and Phase 3 studies. The company is committed to delivering up to 900 million doses to the African Union and COVAX by 2022, ensuring accessibility amid the pandemic.
Johnson & Johnson (NYSE: JNJ) announced key appointments to its Executive Committee, following the retirement of Michael Sneed, effective April 1, 2022. Joaquin Duato will succeed Alex Gorsky as CEO on January 3, 2022. New executive roles include Vanessa Broadhurst as Executive VP of Global Corporate Affairs and Mathai Mammen as Executive VP of Pharmaceuticals, R&D. The leadership changes aim to strengthen company strategy and execution, as highlighted by Duato, who emphasized the team's dedication to the company's mission.
On December 5, 2021, Johnson & Johnson (NYSE: JNJ) announced preliminary findings from a study indicating that a booster shot of its COVID-19 vaccine, Ad26.COV2.S, significantly enhances antibody and T-cell responses when administered six months post a two-dose regimen of BNT162b2. Conducted by Dan Barouch, M.D., Ph.D., the study suggests a mix-and-match approach could yield superior immune responses. Results also align with previous UK studies showcasing increased immunogenicity with Johnson & Johnson's vaccine. The CDC recommends this booster for all eligible individuals.
Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) will present data from six studies on its respiratory syncytial virus (RSV) vaccine candidate at the Eighth European Scientific Working Group on Influenza meeting. Highlights include findings from the Phase 2b CYPRESS trial, showing 80% effectiveness against lower respiratory infections. The vaccine candidate has received Breakthrough Therapy Designation from the FDA and is currently in Phase 3 trials. The urgent need for an RSV vaccine remains, as no effective treatments exist for older adults at high risk.
Johnson & Johnson (NYSE: JNJ) announced plans to spin off its Consumer Health business, creating two independent companies. The split aims to enhance focus, agility, and innovation in healthcare, positioning the new Johnson & Johnson as a leader in pharmaceuticals and medical devices, projected to generate $77 billion in revenue for FY 2021. The New Consumer Health Company will be a global leader in health products with $15 billion projected revenue. The separation is expected to be tax-free for U.S. federal purposes and is targeted for completion within 18-24 months, pending regulatory approvals.
Johnson & Johnson (NYSE: JNJ) announced a partnership with the U.S. Government and Gavi to distribute its single-shot COVID-19 vaccine via the COVAX Humanitarian Buffer. This initiative aims to reach vulnerable populations in conflict zones and areas lacking government vaccination campaigns. The first vaccine deliveries are set for the coming days. The company plans to supply up to 900 million doses on a not-for-profit basis, highlighting its commitment to equitable global access in the fight against the pandemic.
Johnson & Johnson (NYSE: JNJ) has announced a $5 million endowment to Research!America to establish an annual award aimed at recognizing significant contributions to public health. This award will be part of the 26th annual Research!America Advocacy Awards Program. The initiative highlights leaders tackling key health issues like smoking cessation and COVID-19 collaboration. Notable awardees include Matthew Myers, Bill Novelli, and Vivian W. Pinn, MD, who have made significant impacts in public health. The company emphasizes its commitment to advancing global health.
FAQ
What is the current stock price of Johnson & Johnson (JNJ)?
What is the market cap of Johnson & Johnson (JNJ)?
What are the main business segments of Johnson & Johnson?
What recent developments have there been in Johnson & Johnson's pharmaceutical division?
What products are included in Johnson & Johnson’s consumer health segment?
What is CARVYKTI®?
What percentage of Johnson & Johnson's revenue is generated in the United States?
What is the focus of Johnson & Johnson’s medical devices segment?
What changes are happening with Johnson & Johnson’s consumer health division?
How does Johnson & Johnson contribute to global healthcare?
Where can I find more information about Johnson & Johnson?
What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?
